Aspen Pharmacare (APN) investor relations material

Executive summary

• H1 2026 results reflect a strategic reset with strong Commercial Pharma growth, especially in emerging markets, but group performance was offset by a significant Manufacturing decline due to the loss of a major mRNA contract.

• The APAC divestment is progressing and expected to eliminate or materially reduce net debt, providing significant balance sheet flexibility and reshaping the business toward higher-growth regions.

• Free cash flow exceeded expectations, supported by lower CapEx, reduced working capital, and strong operational cash generation.

• Management targets restoration of EBITDA to ZAR 9.6 billion by FY 2027, focusing on organic growth and operational improvements.

• One-off restructuring costs and settlement of the mRNA contract dispute impacted earnings, with H1 2026 considered transitional and stronger H2 2026 expected.

Financial highlights

• Group revenue declined 4% year-over-year to ZAR 21.1 billion, mainly due to Manufacturing segment decline.

• Normalized EBITDA was ZAR 5.1 billion, a 13% decrease from the prior year.

• Normalized headline earnings per share (HEPS) fell 21% to ZAR 5.75 (575 cents); headline EPS dropped 35% to 417.4 cents.

• Free cash flow improved to just under ZAR 2 billion for the half, with a cash conversion rate of 193%.

• Net debt reduced to ZAR 28.6 billion from ZAR 31.2 billion in June 2025; leverage ratio at 3.4x.

Outlook and guidance

• Commercial Pharma expected to deliver mid-single-digit CER revenue growth and double-digit CER EBITDA growth for FY 2026.

• Manufacturing EBITDA expected to be in line with the prior year, with operational improvements offsetting contract losses.

• Group targets double-digit normalized HEPS growth (CER) for FY 2026 and at least double H1 EBITDA in H2 2026.

• APAC divestment proceeds will significantly reduce net debt and enhance balance sheet flexibility.

• CapEx to decline by ZAR 1.3 billion in FY 2026, with further reduction targeted for FY 2027.